The US Food and Drug Administration has cleared French drugmaker Sanofi-Aventis and USA-based Procter & Gamble Pharmaceuticals' Actonel with Calcium (risedronate sodium/calcium carbonate), which is designed to provide the fracture protection of its predecessor but with the added benefit of conveniently-packaged calcium tablets.
According to the firm, the product, which is marketed by The Alliance for Better Bone Health, a collaboration between the two groups, is the first prescription osteoporosis therapy to include calcium.
"Calcium is a critical component to the effectiveness of osteoporosis therapy," stated Steven Goldstein, professor of obstetrics and gynecology at the New York University School of Medicine. He added: "Actonel with Calcium is an important new tool that helps simplify the osteoporosis regimen by conveniently delivering two important elements - the bisphosphonate and the calcium - in one unique package."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze